Claire Mazumdar - Sep 12, 2024 Form 3 Insider Report for Bicara Therapeutics Inc. (BCAX)

Role
Chief Executive Officer, Director
Signature
/s/ Lara Meisner, Attorney-in-Fact
Stock symbol
BCAX
Transactions as of
Sep 12, 2024
Transactions value $
$0
Form type
3
Date filed
9/12/2024, 09:09 PM

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding BCAX Common Stock 310K Sep 12, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BCAX Stock Option (Right to Buy) Sep 12, 2024 Common Stock 99.3K $4.10 Direct F1
holding BCAX Stock Option (Right to Buy) Sep 12, 2024 Common Stock 48.7K $4.44 Direct F2
holding BCAX Stock Option (Right to Buy) Sep 12, 2024 Common Stock 16.2K $4.44 Direct F3
holding BCAX Stock Option (Right to Buy) Sep 12, 2024 Common Stock 138K $3.79 Direct F4
holding BCAX Stock Option (Right to Buy) Sep 12, 2024 Common Stock 326K $3.79 Direct F5
holding BCAX Stock Option (Right to Buy) Sep 12, 2024 Common Stock 595K $5.45 Direct F6
holding BCAX Stock Option (Right to Buy) Sep 12, 2024 Common Stock 1.14M $9.24 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying this option vest in sixteen equal quarterly installments following November 8, 2021, subject to the Reporting Person's continued service on each such vesting date.
F2 The shares underlying this option vest in twelve equal quarterly installments following October 4, 2022, subject to the Reporting Person's continued service on each such vesting date.
F3 The shares underlying this option vest in four equal quarterly installments following October 4, 2025, subject to the Reporting Person's continued service on each such vesting date.
F4 The shares underlying this option vest in sixteen equal quarterly installments following April 5, 2023, subject to the Reporting Person's continued service on each such vesting date.
F5 The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date.
F6 The shares underlying this option vest in sixteen equal quarterly installments following December 14, 2023, subject to the Reporting Person's continued service on each such vesting date.
F7 The shares underlying this option vest in sixteen equal quarterly installments following August 6, 2024, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney